Better Health for All

No specific, concrete evidence was found in the provided articles to assess QuidelOrtho Corporation against any of the 'Better Health for All' KPIs.

All articles contained placeholder text and explicitly stated a lack of relevant data, preventing any scoring.

Fair Money & Economic Opportunity

QuidelOrtho Corporation is a global provider of diagnostic healthcare solutions, not a financial institution.

The company's core business involves developing, manufacturing, and marketing diagnostic tests and equipment. The 'Fair Money & Economic Opportunity' value specifically evaluates activities related to lending, insuring, moving, or storing money, and how financial institutions democratize access to fair financial services. As QuidelOrtho does not offer these types of financial services or products, all KPIs related to consumer financial services, lending practices, fee structures, or customer financial data are not applicable to its business model. Therefore, each KPI is assigned a score of 0, as per the rubric's definition for companies whose core business lies outside finance or do not offer relevant financial products.

Fair Pay & Worker Respect

The CEO's total compensation was 168 times the median employee pay in the 2024 fiscal year.

Approximately 15% of global associates were covered by collective bargaining agreements or works councils in 2023. The total recordable injury rate (TRIR) was 0.66 per 200,000 hours in 2023. In the UK, the median gender pay gap was 1.74% in 2023. The employee engagement score was 85% in 2023. The voluntary employee turnover rate was 8.8% in 2023. The company reported eight incidents of discrimination through its ethics hotline in 2023 and received a $13,132 penalty for a workplace safety or health violation in 2025.

Fair Trade & Ethical Sourcing

No specific, quantitative evidence was found across the provided articles to score any of the KPIs for Fair Trade & Ethical Sourcing. The articles discuss policies, codes of conduct, and efforts related to conflict minerals due diligence, including identifying 49 smelters potentially sourcing from conflict-affected areas and 35 of these being RMAP-compliant.

However, they do not provide metrics such as the percentage of fair-trade certified spend, average audit frequency for tier-1 suppliers, number of forced or child labor incidents, traceability coverage across all tiers, remediation speed, the percentage of all contracts with enforceable ethical clauses, the share of spend on high-risk materials, or the percentage of the procurement budget directed to diverse suppliers.

Honest & Fair Business

QuidelOrtho has a formal whistleblower policy, effective August 22, 2022, covering accounting, internal controls, and auditing matters.

It offers anonymous reporting via a 24/7 ethics hotline and online portal, explicitly prohibiting retaliation. The Chief Compliance Officer acknowledges complaints and communicates significant ones to the Audit Committee within three business days. The company's S&P Global CSA score is 23, placing its ESG controversy score in the bottom quartile. For audit coverage, approximately 62% of Ortho's external manufacturers and 40% of its high and medium-risk direct material suppliers were subject to third-party audits, while 84% of Quidel's high-impact suppliers were audited. The company has an Anti-Bribery/Anti-Corruption Policy, with mandatory employee training and an independent third-party-overseen hotline for reporting concerns. However, its 2022 GHG inventory was not third-party verified, with future plans for verification. The company states that all transactions giving rise to a conflict of interest involving a director, executive officer, or principal financial officer must be approved by the Board, and a material interest is defined as holding 5% or more of equity or voting interest.

Kind to Animals

QuidelOrtho states in its 2024 Sustainability Report that it does not undertake or outsource any animal testing to any third party, indicating a global corporate ban on animal testing.

This policy implies that zero animals are used in testing annually. However, the company's products include those that utilize primary animal cell lines, specifically monkey kidney (rhesus) and rabbit kidney (New Zealand white) cell lines, for detecting human illnesses. Additionally, one product, the MICROVUE™ Pan-Specific C3 Reagent Kit, is designed for *in vitro* and *in vivo* research use in various animal species, though it is not for diagnostic procedures.

No War, No Weapons

QuidelOrtho Corporation's core business is diagnostic healthcare solutions, and there is no evidence of revenue from arms or defense contracts, nor R&D investment in dual-use technologies with military applications.

The company states it complies with economic sanctions regulations adopted by the U.S., UK, EU, and other applicable regulations, indicating robust compliance controls are in place. The company's conflict minerals policy is designed to align with the UN Guiding Principles on Business and Human Rights and complies with OECD Due Diligence Guidance. However, the 2022 Conflict Minerals Report identified 344 valid smelters in the supply chain, with 46 potentially sourcing from conflict-affected areas. Of these, 34 were audited and recognized as conformant to RMAP, 12 were subject to due diligence, and 2 were actively working towards RMAP conformance. The presence of 46 smelters potentially sourcing from conflict-affected areas, with only 34 conformant, indicates that less than 10% of the supply chain is verified conflict-free based on the identified smelters. While the policy aims for UNGP alignment, the significant number of non-conformant or unverified smelters suggests uneven implementation across divisions.

Planet-Friendly Business

No specific, quantifiable evidence was found in the provided articles regarding QuidelOrtho Corporation's performance across any of the Planet-Friendly Business KPIs. The articles discuss general sustainability trends in the healthcare industry, provide tips for sustainable sourcing,

or outline the sustainability strategies and targets of other companies, but do not offer concrete data or actions attributable to QDEL.US.

Respect for Cultures & Communities

The provided articles do not contain specific, quantitative data points for any of the KPIs related to 'Respect for Cultures & Communities'. While there is information on general charitable giving and employee diversity, it does not directly address formal partnerships with community groups, cultural impact assessments, local employment ratios, grievance mechanisms for communities, cultural preservation investments, or specific cultural sensitivity training completion rates.

Therefore, no KPIs can be scored based on the evidence provided.

Safe & Smart Tech

QuidelOrtho reported no material cybersecurity threats or incidents affecting the company since the beginning of the last fiscal year, and no specific incidents of unauthorized data use.

The company has identity and access management processes, including multi-factor authentication and role-based controls, and limits access to information to what is necessary for official duties. Security by design is mentioned as a principle. Vulnerability management includes scanning, penetration testing, and standardization of cybersecurity architecture. The company has a vulnerability disclosure policy that outlines how it handles reports from security researchers. They align with applicable cybersecurity regulations and industry standards, including FDA and CISA regulations. Regular penetration testing and vulnerability scanning are conducted.